Session Details

U032 Malignant Melanoma: Molecular Diagnostics, Emerging Therapies, and the Microbiome

Sat, Mar 20, 7:30 AM - 8:30 AM
1 CME Available Focus Session

DESCRIPTION

The session will combine formal lectures and interactive presentations. Different melanoma types and borderline melanocytic lesions will be discussed, in light of the current WHO classification, emphasizing a combined approach utilizing clinico-pathological presentation and new molecular techniques. Novel therapies will also be discussed including targeted therapy and immunotherapy, with emphasis on their efficacy and side effects. The session will also look to the future of melanoma and the impact of the microbiome on prognosis and response to therapy. The session will be directed to general dermatologists, dermato-oncologists, and dermatopathologists.

LEARNING OBJECTIVES

1.

Recognize the morphology and molecular pathology of different melanoma sub-types and borderline lesions according to the WHO classification system, and determine the appropriate patient management algorithms.

2.

Discuss available molecular tests for diagnosis and prognosis and their application. Discuss new treatment options such as targeted therapy, immune blockade therapy, neoantigen therapy and combination therapies, and the management of their side effects.

3.

Describe and discuss the microbiome as well as its potential import on melanoma diagnosis and response to therapy.

DIRECTOR

Emily Y. Chu, MD, PhD, FAAD

Emily Y. Chu, MD, PhD, FAAD

University of Pennsylvania

SPEAKER

Justine Cohen, DO

Justine Cohen, DO

Dana-Farber Cancer Institute

DISCLOSURES

Emily Y. Chu, MD, PhD, FAAD

No financial relationships exist with ineligible companies.

Justine Cohen, DO

Bristol-Myers Squibb – Advisory Board(Honoraria); Pfizer Inc. – Consultant (1099 relationship)(Honoraria); Regeneron Pharmaceuticals Inc – Consultant (1099 relationship)(Honoraria); Replimune – Advisory Board(Honoraria);